Yazar "Töret, Ersin" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    CMV-specific T-Cells for Treatment of CMV infection after hematopoietic stem cell transplantation in a pediatric case: First application in Turkey
    (Galenos Yayincilik, 2020) Celilova, Sevil; Töret, Ersin; Adaklı Aksoy, Başak; Ovalı, Ercüment; Bozkurt, Ceyhun
    Cytomegalovirus (CMV) infection is still a major complication after allogeneic hematopoietic stem cell transplantation (HSCT) [1,2]. Unfortunately, prolonged antiviral treatment of CMV infection causes a delayed CMV-specific immune reconstitution. At this point, adoptive immunotherapy by CMV-specific T-cells can control CMV infection or provide immune reconstruction
  • Küçük Resim
    Öğe
    Comparison of hematopoietic stem cell transplantation results in patients with ?-thalassemia major from three different graft types
    (Taylor & Francis Online, 2021) Aydoğdu, Selime; Töret, Ersin; Adaklı Aksoy, Başak; Aydın, Muhammed Fatih; Erol Cipe, Funda; Bozkurt, Ceyhun; Fışgın, Tunç
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the curative therapy for ?-thalassemias that induces severe life-threatening complications. The human leukocyte antigen (HLA) registries and umbilical cord blood banks have carried out diligent searches to find matched unrelated donors (MUDs) for about 70.0% of patients from 2000 onwards. The chance of finding a non-sibling fully matched family donors is higher in some ethnic groups in which consanguineous marriages are common. We have studied and compared transplant complications and outcomes in different graft types (sibling, non-sibling family and unrelated). The non-sibling matched family donor (MFD) group consisted of four mothers, three fathers, five cousins, one paternal uncle and one paternal aunt. There was no significant difference in the mean transfused CD34+ cells, engraftment, median days of neutrophil and platelet recovery were achieved (p?>?0.05). The distribution of postttransplant complication did not show any significant difference between groups (p?>?0.05). In univariate analysis and multivarite analyses, age, gender, Pesaro risk group (I-II vs. III) and ABO incompatibilty demonstrated a significant difference in disease free survival (p?